JAKKS PACIFIC INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that JAKKS PACIFIC INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $331.25M | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $383.96M | Mar 15, 2016 |
| FY2015 | Dec 31, 2013 | $302.07M | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $312.17M | Mar 16, 2015 |
| FY2013 | Dec 31, 2011 | $383.80M | Mar 17, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $570.67M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $691.04M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $711.56M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $796.19M | Mar 6, 2025 |
| FY2021 | Dec 31, 2021 | $187.96M | Mar 16, 2022 |
| FY2021 | Sep 30, 2021 | $236.96M | Mar 16, 2022 |
| FY2021 | Jun 30, 2021 | $112.35M | Mar 16, 2022 |
| FY2021 | Mar 31, 2021 | $83.84M | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | $128.27M | Mar 16, 2022 |
| FY2021 | Sep 30, 2020 | $242.29M | Mar 16, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $132.33M | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $236.70M | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $105.78M | Mar 18, 2019 |
| FY2018 | Mar 31, 2018 | $93.00M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $136.63M | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $262.41M | Mar 18, 2019 |
| FY2018 | Jun 30, 2017 | $119.57M | Mar 18, 2019 |
| FY2018 | Mar 31, 2017 | $94.51M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $167.03M | Mar 16, 2018 |
| FY2016 | Sep 30, 2016 | $302.79M | Mar 16, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.08M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $213.02M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $223.35M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $211.29M | Mar 6, 2025 |
| FY2021 | Dec 31, 2021 | $50.04M | Mar 16, 2022 |
| FY2021 | Sep 30, 2021 | $74.92M | Mar 16, 2022 |
| FY2021 | Jun 30, 2021 | $31.90M | Mar 16, 2022 |
| FY2021 | Mar 31, 2021 | $26.09M | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | $42.03M | Mar 16, 2022 |
| FY2021 | Sep 30, 2020 | $74.62M | Mar 16, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $33.92M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $38.41M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $91.41M | Mar 6, 2025 |
| FY2021 | Dec 31, 2021 | ($3.17M) | Mar 16, 2022 |
| FY2021 | Sep 30, 2021 | $36.33M | Mar 16, 2022 |
| FY2021 | Jun 30, 2021 | ($15.08M) | Mar 16, 2022 |
| FY2021 | Mar 31, 2021 | ($24.09M) | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | ($11.34M) | Mar 16, 2022 |
| FY2021 | Sep 30, 2020 | $32.38M | Mar 16, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.22M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $39.68M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $59.11M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $60.97M | Mar 6, 2025 |
| FY2021 | Dec 31, 2021 | $2.93M | Mar 16, 2022 |
| FY2021 | Sep 30, 2021 | $36.74M | Mar 16, 2022 |
| FY2021 | Jun 30, 2021 | $1.82M | Mar 16, 2022 |
| FY2021 | Mar 31, 2021 | ($2.72M) | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | $1.13M | Mar 16, 2022 |
| FY2021 | Sep 30, 2020 | $37.51M | Mar 16, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.80M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $10.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $9.30M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $9.79M | Mar 6, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.86M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $173.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $164.25M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $150.02M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $144.19M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $134.86M | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | $99.58M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $185.14M | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $205.22M | May 13, 2020 |
| FY2018 | Dec 31, 2016 | $205.92M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.49M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $38.95M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $66.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $86.10M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | ($5.88M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $43.57M | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | $21.83M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | ($624.0K) | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $11.39M | May 13, 2020 |
| FY2018 | Dec 31, 2016 | $16.72M | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.56M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $11.25M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $8.91M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $10.39M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $8.22M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $8.27M | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | $9.42M | Mar 16, 2022 |
| FY2020 | Dec 31, 2018 | $11.77M | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $14.93M | May 13, 2020 |
| FY2018 | Dec 31, 2016 | $14.77M | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $442.20M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $444.87M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $398.95M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $405.34M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $357.05M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $329.37M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $365.22M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $342.84M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $370.35M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $464.30M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.09M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $204.04M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $202.84M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $254.15M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $296.07M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $314.69M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $360.72M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $291.19M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $275.84M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $329.10M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $249.11M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $240.33M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $189.41M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $145.70M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $56.57M | Mar 6, 2025 |
| FY2023 | Dec 31, 2020 | $11.73M | Mar 15, 2024 |
| FY2022 | Dec 31, 2019 | $2.94M | Apr 14, 2023 |
| FY2021 | Dec 31, 2018 | $50.74M | Mar 16, 2022 |
| FY2020 | Dec 31, 2017 | $93.54M | Mar 19, 2021 |
| FY2017 | Dec 31, 2016 | $134.29M | Mar 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.08M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $35.11M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $35.08M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $35.08M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $35.08M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $35.08M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $35.08M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $35.08M | May 13, 2020 |
| FY2019 | Dec 31, 2017 | $35.38M | May 13, 2020 |
| FY2018 | Dec 31, 2016 | $43.21M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.02M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($39.69M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($73.61M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($112.02M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($203.43M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($197.42M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($183.15M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($127.60M) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($85.23M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($2.15M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.20M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $69.94M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $72.35M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $85.30M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $44.52M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $87.95M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $61.61M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $53.28M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $64.98M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $86.06M | Mar 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $68.90M | Apr 14, 2023 |
| FY2021 | Dec 31, 2021 | $98.51M | Mar 16, 2022 |
| FY2020 | Dec 31, 2020 | $34.13M | Mar 19, 2021 |
| FY2020 | Dec 31, 2019 | $52.66M | Mar 19, 2021 |
| FY2012 | Dec 31, 2012 | $70.71M | Mar 15, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 9 | Mar 6, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 16, 2022 |
| FY2021 | Sep 30, 2021 | 4 | Mar 16, 2022 |
| FY2021 | Jun 30, 2021 | (2) | Mar 16, 2022 |
| FY2021 | Mar 31, 2021 | (4) | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | (2) | Mar 16, 2022 |
| FY2021 | Sep 30, 2020 | 8 | Mar 16, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 8 | Mar 6, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 16, 2022 |
| FY2021 | Sep 30, 2021 | 3 | Mar 16, 2022 |
| FY2021 | Jun 30, 2021 | (2) | Mar 16, 2022 |
| FY2021 | Mar 31, 2021 | (4) | Mar 16, 2022 |
| FY2021 | Dec 31, 2020 | (2) | Mar 16, 2022 |
| FY2021 | Sep 30, 2020 | 3 | Mar 16, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 11.03M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 10.10M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 9.74M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 9.52M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 5.69M | Mar 16, 2022 |
| FY2022 | Jul 9, 2020 | 4.24M | Apr 14, 2023 |
| FY2022 | Jul 8, 2020 | 42.40M | Apr 14, 2023 |
| FY2020 | Dec 31, 2019 | 3.52M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | 29.17M | May 13, 2020 |